Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-02-08
2011-02-08
Jiang, Dong (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300, C530S388100, C530S388230, C530S809000, C530S351000
Reexamination Certificate
active
07883700
ABSTRACT:
Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells THcells or TH17 cells.
REFERENCES:
patent: 6307024 (2001-10-01), Novak et al.
patent: 6605272 (2003-08-01), Novak et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 6686178 (2004-02-01), Novak et al.
patent: 7473765 (2009-01-01), Novak et al.
patent: 7491800 (2009-02-01), Novak et al.
patent: 2004/0260065 (2004-12-01), Novak et al.
patent: 2007/0014800 (2007-01-01), Novak et al.
patent: 2007/0041974 (2007-02-01), Novak et al.
patent: 2007/0048259 (2007-03-01), Novak et al.
patent: 2007/0048260 (2007-03-01), Novak et al.
patent: 2007/0048845 (2007-03-01), Novak et al.
patent: 2007/0049529 (2007-03-01), Novak et al.
patent: 2007/0054320 (2007-03-01), Novak et al.
patent: 2007/0059825 (2007-03-01), Novak et al.
patent: 2007/0066807 (2007-03-01), Novak et al.
patent: 2007/0066808 (2007-03-01), Novak et al.
patent: 2007/0092485 (2007-04-01), Novak et al.
patent: 2007/0098682 (2007-05-01), Novak et al.
patent: 2007/0098683 (2007-05-01), Novak et al.
patent: 2007/0099269 (2007-05-01), Novak et al.
patent: 2007/0128189 (2007-06-01), Sivakumar et al.
patent: 2007/0166794 (2007-07-01), Novak et al.
patent: 03/103589 (2003-12-01), None
patent: 2004/032857 (2004-04-01), None
patent: 2004/056392 (2004-07-01), None
patent: 2005/037306 (2005-04-01), None
U.S. Appl. No. 11/346,580, filed Feb. 2, 2006, Novak et al.
U.S. Appl. No. 12/179,003, filed Jul. 24, 2008, Sivakumar.
Clegg et al., “Therapeutic opportunities for IL-21,”European Cytokine Network 14(3):28, 2003.
Nelson et al., “Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2,” Proceedings of the American Association for Cancer Research Annual Meeting 44:562, 2003.
Funaro et al., “Monoclonal antibodies and therapy of human cancers,”Biotechnology Advances 18(5):385-401, 2000.
Ozaki et al., “Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6,”J Immunol. 173(9):5361-71, 2004.
Aklulu et al., “Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma,”Ann Oncol. 15(2):1109-14, 2004.
Moroz et al., “IL-21 enhances and sustains CD8+ T cell responses to achieve duragble tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21,”J Immunol. 173(2):900-9, 2004.
O'Shea et al., “Jak3 and the pathogenesis of severe combined immunodeficiency,”Mol Immunol. 727-37, 2004.
Sivakumar et al., Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumor responses,:Immunology 112(2):177-82, 2004.
Munshi, “Recent advances in the management of multiple myeloma,”Semin Hematol. 2(4):21-6, 2004.
Rowshani et al., “Effects of CD25 monoclonal antibody on proliferative and effector functions of alloactivated human T cells in vitro,”Eur J Immunol. 34(3):882-99, 2004.
Sievers et al., “IL-21 enhances trastuzumab-mediated killing of breast cancer cell lines in vitro,”Breast Cancer Res. And Treatment S1(0):6075, 2004.
Kindsvogel et al.., “IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo,”J. Clin. Oncol. 22(14S):2581, 2004.
Hughes et al., “Interleukin 21 efficacy in a mouse model of metastatic renal cell carcinoma,”J. Clin. Oncol. 22(14S)2598, 2004.
Sivakumar et al., “interleukin-21 Elicits Durable T and NK Cytotoxicity: Basic Biology to Clinical Trials.,”J. Immunother. 27(6):S56, 2004.
Hughes et al., “Mechanisms of IL-21 Enhancement of Rituximab Efficacy in a Lymphoma Xenograft Model,”Blood 104(11):394A, 2004.
Rastetter et al., “Rituximab: expanding role in therapy for lymphomas and autoimmune diseases,”Annu Rev. Med. 55:477-503, 2004.
Akamatsu et al., “Selected IL-21R Expression and Apoptosis Induction by IL-21 in Follicular Lymphoma,”Blood 104(11):629A, 2004.
Ueda et al., “Expression of Functional IL-21 Receptor on adult T-cell Leukemia Cells,”Blood 102(11), 2003.
Gitlitz et al., “Cytokine-based therapy for metastatic renal cell cancer,”Urol Clin North Am.(3):589-600, 2003.
Ma et al., IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamms,J. Immunol. 171(2):608-15, 2003.
Mehta et al., “IL-21 induces the apoptosis of resting and activated primary B cells,”J Immunol.. 170(8):4111-8, 2003.
Strengell et al., “IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response,”J Immunol. 169(7):3600-5, 2002.
Nelson et al., “Anti-tumor Effects of Interleukin 21,” Immunobiology of Lymphomna abstr. 593, 2002.
Parrish-Novak et al., “Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function,”Nature 408(6808):57-63, 2000.
Ro et al., “IL-21 is a Growth and Survival Factor for Human Myeloma Cells,”Blood 98(11):abst. 3216, 2001.
Stauber et al., “Crystal structure of the IL-2 signaling complex: Paradigm for a deterotrimeric cytokine receptor,”PNAS 103(8):2788-1793, 2006.
Zhang et al., “Human IL-21 and IL-4 bind to partially overlapping epitopes of common γ-chain,”Biochem and Biophys Res Comm 300:291-296, 2003.
Habib et al., “The common γ Chain (γc) Is a Required Signaling Component of the IL-21 Receptor and Supports IL-21-Indiced Cell Proliferation via JAK3,”Biochemistry 41:8725-8731, 2002.
Olosz et al., “Structural Basis for Binding Multiple Ligands by the Common Cytokine Receptor γ-Chain,”J Biol. Chem. 277(14):12047-12052, 2002.
Bondensgaard et al., “The existence of multiple conformers of interleukin-21 directs engineering of a superpotent alanlgue,”J. Biol. Chem. 282(32):23326-36, 2007.
Weidemann et al., “Beyond dimerization: a membrane-dependent activation model for interleukin-4 receptor-mediated signaling,”J. Mol Biol 366(5):1365-73, 2007.
Brtandt et al., “Generation of Antagonists by Amino Acid Replacement in the D-Helix of Human IL-21,”J. Leuk Biol Supp. 2001.
Dillon Stacey R.
Jaspers Stephen R.
Krejsa Cecile M.
Ramsdell Frederick J.
Rixon Mark W.
Jiang Dong
Lewis Michelle L.
Sawislak Deborah A.
ZymoGenetics Inc.
LandOfFree
Anti-human IL-21 monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-human IL-21 monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-human IL-21 monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632507